Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of ...
Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.
The US Food and Drug Administration (FDA) has approved Supernus Pharmaceuticals’ Onapgo (apomorphine hydrochloride) injection ...
ONAPGOis the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s ...
The FDA on Tuesday signed off on Supernus Pharmaceuticals’ apomorphine hydrochloride injection—to be marketed under the brand ...
Three strikes and you’re out? Not for Supernus Pharmaceuticals and its Parkinson’s disease infusion pump. | The device is ...
It is fourth time lucky for Supernus Pharmaceuticals, as its Parkinson’s specialist finally receives US approval for Onapgo ...
The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat ...
The FDA has approved Onapgo, the first subcutaneous apomorphine device to treat motor fluctuations in adults with Parkinson’s disease, according to the manufacturer.In a press release, Supernus ...
Supernus Pharmaceuticals has won Food and Drug Administration approval for its Onapgo device to treat patients with Parkinson's disease.
Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, approved ONAPGO injection, formerly known as ...
Padmanabh P. Bhatt, Senior Vice President of Intellectual Property and Chief Scientific Officer at Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a company that InvestingPro data shows maintains ...